Alright, lets review what most people already seem to realize.
The shares that you are referring to are going to be restricted for at least one year. Those shares will belong to the private equity interest holders of the (then) private company Oncolix.
Those shareholders are a collection of accredited investors who represent endowments, trusts, institutional investors and high net worth individuals.
The only shares that will be hitting the public float anytime soon, are the interest payments on the note recently issued.
They are two separate things.
The $4M note has interest payments due @ 10% annum.
A $4M note, due interest annually is $400,000. That makes for a quarterly interest payment of $100,000 that the company has the option to deliver in the form of cash or shares.
Yes, there is some equity due along with interest, but the terms negotiated by Oncolix make those conditions at the discrepancy of the company and the holder.
Those are the only shares that could possibly hit the float anytime soon. I consider those shares to be largely irrelevant given the AEPP share structure and public float.
While some claim that AEPP is illiquid, we could also say that it is thinly traded. Both statements would be correct. It just depends on how you want to frame it.
Either way equals volatility upon news, good or bad.
We already know that some brokers and third party market data providers show the name change, while others do not.
As some have stated here already, Oncolix has already received the new cusip number. We are just waiting for FINRA internal system changes.
Once the FINRA change is announced, all brokers and market providers will be providing updates in a timely and uniform fashion.
The Oncolix SEC CIK# has already been documented and linked to.
The FINRA internal system change is the first FLE event that could have a positive impact on the stock.
The second would be the appointment of a few credible independent BOD members.
The third would be the re-instatement of our OTCQB tier.
The fourth would be any S-1s and S-1As showing progress on the eventual goal of a certnas/certnyse filing that would lead to being listed on the NASDAQ or NYSE.
The fifth would be any progress regarding the advancement of FDA clinical trials.
The sixth would be the addition of any other endowments, trusts or institutional investment.
The seventh would be the announcement of any additional grants from either the US government or the Susan G. Komen foundation.
Both have provided grants for prolactin research in the past.
I know that is a lot to digest.
I hope everyone finds it helpful or at the very least, finds flaws that can contribute to a legitimate debate on where we are here with AEPP and Oncolix.
IMO and FWIW.
